Matthew Boeckman, MD
Pain Medicine · del City, OKNPI 1861641961
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Abbott at 34.1% of the total. Reporting peaked in 2019 at $1,590 and has fallen 80.8% since, to $306 in 2025.
Across 496 payments — averaging $12.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Collegium Pharmaceutical, Inc.$730
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$567
- Biodelivery Sciences International, Inc.$358
- Pfizer$306
- Amgen$276
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,936100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 182 | $2,034 |
| Collegium Pharmaceutical, Inc. | 58 | $730 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 42 | $567 |
| Biodelivery Sciences International, Inc. | 43 | $358 |
| Pfizer | 38 | $306 |
| Amgen(2 entities) | 29 | $276 |
| Merck | 17 | $240 |
| Scilex Pharmaceuticals Inc. | 14 | $218 |
| AstraZeneca | 15 | $200 |
| Eisai Inc. | 16 | $196 |
| Boston Scientific | 3 | $132 |
| Redhill Biopharma Inc. | 7 | $116 |
| Daiichi Sankyo Inc. | 6 | $109 |
| Shionogi Inc | 4 | $89 |
| Forte Bio-pharma LLC | 1 | $62 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| IBSA Pharma Inc. | 3 | $41 |
| Nevro Corp. | 2 | $39 |
| Sentynl Therapeutics, Inc. | 3 | $39 |
| Vertex | 2 | $38 |
| Almatica Pharma LLC | 2 | $33 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Valinor Pharma, LLC | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| GRT US Holding, Inc. | 2 | $17 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,965 in reported general payments places this provider in the 65th percentile of 68 pain medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 69 | $51,151 |
| Buprenorphine | 207 | $40,197 |
| BelsomraSuvorexant | 66 | $30,774 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,089 | $25,638 |
| MovantikNaloxegol Oxalate | 39 | $15,832 |
| Xtampza ErOxycodone Myristate | 41 | $12,368 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 451 | $10,644 |
| OxycontinOxycodone Hcl | 27 | $9,267 |
| Gabapentin | 531 | $6,789 |
| DayvigoLemborexant | 15 | $5,141 |
| Pregabalin | 218 | $3,755 |
| Morphine Sulfate ErMorphine Sulfate | 125 | $2,721 |
| Baclofen | 149 | $2,326 |
| Lidocaine | 18 | $2,089 |
| Tizanidine Hcl | 194 | $1,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $730 | $63,519110 claims |
| MerckBelsomra | $240 | $30,77466 claims |
| Redhill Biopharma Inc.Movantik | $116 | $15,83239 claims |
| Eisai Inc.Dayvigo | $196 | $5,14115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 68 pain medicine providers in Oklahoma.
Other pain medicine in del City
- Sailesh ArulkumarOklahoma City$162K
- Emily PollardOklahoma City$134K
- James StephensNorman$39K
- Tyler PhillipsOklahoma City$36K
- Jeffrey MillerMoore$33K
- Nevinson SamEdmond$27K
- John NelsonOklahoma City$26K
- Rafael JustizOklahoma City$25K
- Bruce MackeyEdmond$14K
- Brian TorgersonTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.